Targeting FSTL1 prevents tumor bone metastasis and consequent immune dysfunction

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6185-6193

  Kudo Saito, Chie ^a   Fuwa, Takafumi ^a   Murakami, Kouichi ^a   Kawakami, Yutaka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD44V ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; FOLLISTATIN; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 10; POLYETHYLENEIMINE COMPLEXED SIRNA FSTL1; PROTEIN FSTL1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SNAIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; INTERFERON PRODUCTION; METASTASIS INHIBITION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; RNA INTERFERENCE; SUBCUTANEOUS TISSUE TUMOR; TROPISM; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; BONE MARROW CELLS; BONE NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; FOLLISTATIN-RELATED PROTEINS; HUMANS; MELANOMA, EXPERIMENTAL; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84886003644     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1364     Document Type: Article

References (26)

1. Weilbaecher KN, Guise TA, McCauley LK Cancer to bone: a fatal attraction. Nat Rev Cancer 2011; 11:411-25.
2. Wang J, Loberg R, Taichman RS The pivotal role of CXCL12 (SDF-1)/ CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006; 25: 573-87.
3. Burger JA, Kipps TJ CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107:1761-7.
4. Lipton A. Future treatment of bone metastases. Clin Cancer Res 2006; 12:6305s-08s.
5. Lu Y, Chen Q, Corey E., Xie W, Fan J, Mizokami A., et al Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis 2009; 26:161-9.
6. Cai Z, Chen Q, Chen J., Lu Y, Xiao G, Wu Z., et al Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia 2009; 11:228-36.
7. Zhau HE, Odero-Marah V, Lue H.W., Nomura T., Wang R, Chu G, et al Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 2008; 25: 601-10.
8. Feuerer M, Beckhove P, Garbi N., Mahnke Y, Limmer A, Hommel M., et al Bone marrow as a priming site for T-cell responses to bloodborne antigen. Nat Med 2003; 9:1151-7.
9. Kudo-Saito C., Shirako H, Takeuchi T., Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009; 15:195-206.
10. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8:726-36.
11. Bianchi G, Borgonovo G, Pistoia V., Raffaghello L. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. Histol Histopathol 2011; 26: 941-51.
12. Kudo-Saito C., Shirako H, Ohike M., Tsukamoto N, Kawakami Y. CCL2 is critical for immunosuppression to promote cancer metastasis. Clin Exp Metastasis 2013; 30:393-405.
13. Beyer Nardi N., da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol 2006:249-82.
14. Weidle UH, Eggle D, Klostermann S., Swart GW ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics 2010; 7:231-43.
15. Karnoub AE, Dash AB, Vo A.P., Sullivan A., Brooks MW, Bell GW, et al Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557-63.
16. Tanaka M, Murakami K, Ozaki S., Imura Y, Tong XP, Watanabe T, et al DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1-analysis of their binding with TGF-beta superfamily proteins. Febs J 2010; 277:4278-89.
17. Ouchi N, Asaumi Y, Ohashi K., Higuchi A, Sono-Romanelli S, Oshima Y, et al DIP2A functions as a FSTL1 receptor. J Biol Chem 2010; 285: 7127-34.
18. Adams D, Larman B, Oxburgh L. Developmental expression of mouse Follistatin-like 1 (Fstl1): dynamic regulation during organogenesis of the kidney and lung. Gene Expr Patterns 2007; 7:491-500.
19. Miyamae T, Marinov AD, Sowders D, Wilson D.C., Devlin J., Boudreau R, et al Follistatin-like protein-1 is a novel proinflammatory molecule. J Immunol 2006; 177:4758-62.
20. Li D, Wang Y, Xu N., Wei Q, Wu M, Li X., et al Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis. Arthritis Res Ther 2011; 13:R17.
21. Hambrock HO, Kaufmann B, Muller S., Hanisch FG, Nose K, Paulsson M, et al Structural characterization of TSC-36/Flik: analysis of two charge isoforms. J Biol Chem 2004; 279:11727-35.
22. Genovese JA, Spadaccio C, Rivello H.G., Toyoda Y., Patel AN Electrostimulated bone marrow human mesenchymal stem cells produce follistatin. Cytotherapy 2009; 11:448-56.
23. + regulatory T cells upon mesenchymal stem celllymphocyte interaction. Haematologica 2007; 92:881-8.
24. Giuliani M, Fleury M, Vernochet A., Ketroussi F, Clay D, Azzarone B., et al Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS ONE 2011; 6: e19988.
25. Bilic I, Koesters C, Unger B., Sekimata M, Hertweck A, Maschek R., et al Negative regulation of CD8 expression via Cd8 enhancermediated recruitment of the zinc finger protein MAZR. Nat Immunol 2006; 7:392-400.
26. Jenkinson SR, Intlekofer AM, Sun G, Feigenbaum L., Reiner SL, Bosselut R. Expression of the transcription factor cKrox in peripheral CD8 T cells reveals substantial postthymic plasticity in CD4-CD8 lineage differentiation. J Exp Med 2007; 204: 267-72.